BIOATLA INC (BCAB) Forecast, Price Target & Analyst Ratings
NASDAQ:BCAB • US09077B1044
0.1677 USD
0 (-1%)
Last: Mar 12, 2026, 01:57 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOATLA INC (BCAB).
Forecast Snapshot
Consensus Price Target
$10.20
+ 5,982.29% Upside
Next Earnings Forecast
Release DateMar 19, 2026
PeriodQ4 / 2025
EPS Estimate-$0.24
Revenue Estimate
ChartMill Buy Consensus
85.71%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$10.20
Upside
+ 5,982.29%
From current price of $0.17 to mean target of $10.20, Based on 7 analyst forecasts
Low
$10.10
Median
$10.20
High
$10.50
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for BCAB. The average price target is 10.2 USD. This implies a price increase of 5982.29% is expected in the next year compared to the current price of 0.1677.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.71%
BCAB was analyzed by 7 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about BCAB.
In the previous month the buy percentage consensus was at a similar level.
BCAB was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-13 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2025-03-31 | Citizens Capital Markets | Maintains | Market Outperform -> Market Outperform |
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-09-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-05-23 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-05 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-25 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-08-02 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-08-02 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-02 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-08-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-15 | JMP Securities | Reiterate | Outperform -> Outperform |
| 2023-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-12 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-04-17 | EF Hutton | Maintains | Buy |
| 2023-04-03 | JP Morgan | Maintains | Overweight |
| 2023-03-28 | BTIG | Maintains | Buy |
| 2023-03-27 | JMP Securities | Maintains | Outperform |
| 2023-03-24 | EF Hutton | Reiterate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 19, 2026
PeriodQ4 / 2025
EPS Estimate-$0.24
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q18.40%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
BCAB is expected to report earnings on 3/19/2026. The consensus EPS estimate for the next earnings is -0.24 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 11M | -100.00% | |||||||||
| EBITDA YoY % growth | -106.94M -12.44% | -128.466M -20.13% | -73.018M 43.16% | -112.2M -53.66% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -108.14M -12.13% | -129.687M -19.93% | -73.943M 42.98% | -74.462M -0.70% | -76.212M -2.35% | -94.592M -24.12% | -72.544M 23.31% | -78.107M -7.67% | -89.498M -14.58% | -99.993M -11.73% | -106.293M -6.30% | |
| Operating Margin | N/A | N/A | -672.21% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -2.74 0.72% | -2.59 5.47% | -1.44 44.40% | -1.10 23.50% | -0.94 14.81% | -1.19 -27.17% | -0.92 23.08% | -0.98 -6.67% | -1.12 -14.58% | -1.25 -11.82% | -1.33 -5.69% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.24 18.40% | -0.20 21.54% | -0.17 45.81% | -0.14 47.11% | -0.29 -18.75% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -19.087M -17.50% | -11.985M 28.13% | -12.015M 28.03% | -12.045M 12.65% | -13.28M 30.42% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
5.41%
EPS Next 5 Year
5.71%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
-14.87%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
BIOATLA INC / BCAB Forecast FAQ
What is the average price target for BIOATLA INC (BCAB) stock?
7 analysts have analysed BCAB and the average price target is 10.2 USD. This implies a price increase of 5982.29% is expected in the next year compared to the current price of 0.1677.
What is the next earnings date for BCAB stock?
BIOATLA INC (BCAB) will report earnings on 2026-03-19, after the market close.
Can you provide the consensus estimates for BIOATLA INC next earnings?
The consensus EPS estimate for the next earnings of BIOATLA INC (BCAB) is -0.24 USD and the consensus revenue estimate is 0 USD.
How do analysts rate BIOATLA INC (BCAB)?
The consensus rating for BIOATLA INC (BCAB) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.